Email updates

Keep up to date with the latest news and content from BMC Infectious Diseases and BioMed Central.

This article is part of the supplement: Abstracts from the First International Science Symposium on HIV and Infectious Diseases (HIV SCIENCE 2012)

Open Access Open Badges Oral presentation

Genotype-specific incidence and clearance rates of human papilloma virus (HPV) infection in HIV-infected women from Pune, India

Arati Mane1*, Amit Nirmalkar1, Arun R Risbud1, Sten H Vermund2, Sanjay M Mehendale3 and Vikrant V Sahasrabuddhe2

Author Affiliations

1 National AIDS Research Institute, Pune, India

2 Vanderbilt University Institute for Global Health, Nashville, USA

3 National Institute of Epidemiology, Chennai, India

For all author emails, please log on.

BMC Infectious Diseases 2012, 12(Suppl 1):O2  doi:10.1186/1471-2334-12-S1-O2

The electronic version of this article is the complete one and can be found online at:

Published:4 May 2012

© 2012 Mane et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Information on HPV genotype-specific incidence and clearance is important to better inform the natural history of cervical neoplasia in context of HIV/AIDS. We conducted a cohort study among HIV-infected women in Pune, India to estimate the genotype-specific HPV incidence and clearance rates.


HIV-infected women underwent baseline and annual follow-up visits for cervical cancer screening and collection of cervicovaginal samples for detection of 37 HPV genotypes by Linear Array polymerase chain reaction (PCR) assay.


A total of 215 eligible participants were followed for a median time of 11 months (range: 8-23 months) with a follow-up period of 223 person-years. Of the 104/215 (48.4 %) HIV-infected women who were HPV-negative at baseline, 12 women were newly detected with HPV at follow-up visit reflecting an incidence rate of 5.4 per 100 person-years. Type-specific incidence rates ranged between 0.45-3.42 per 100 person-years for carcinogenic HPV types and between 0.45-1.79 per 100 person-years for other HPV types. Of the 111/215 (51.6 %) women with HPV at baseline, 21 women cleared all types, reflecting a clearance rate of 9.4 per 100 person-years. Type-specific clearance rates ranged between 0.45-4.48 per 100 person-years for carcinogenic HPV types and between 0.45-4.04 for other HPV types.


This study adds to the scant global data of natural history of HPV infection in HIV-infected women. Knowledge of incidence and clearance rates can inform cost effectiveness and decision analysis models for estimating effectiveness of HPV vaccination and screening strategies for cervical cancer prevention for HIV-infected women.